David Langlais

David Langlais

Dept. of Biochemistry
McGill University
Montreal, Canada

Dr. Langlais completed his Ph. D. with honours in Molecular Biology in 2011 under the supervision of Dr. Jacques Drouin at Universite de Montreal, Montreal, Canada and is currently pursuing postdoctoral research in Dr. Philippe Gros laboratory at McGill University. He is now studying the role of the transcription factors IRF8 and IRF1 in the interferon gamma (IFNg) response to infection. Dr. Langlais and colleagues have demonstrated that IRF8 is critical to mount an appropriate inflammatory response, as the mice are susceptible to M. tuberculosis infections but are resistant to neuroinflammation induced by the cerebral malaria model, P. berghei ANKA.  Dr. Langlais is now exploring the relative role of IRF8 and its binding partner proteins (IRF1 and PU1) in the macrophage transcriptional response to IFNg. He is also evaluating the role of these transcriptional networks in human tuberculosis and malaria infections, still two of the most deadly diseases world-wide. This work may pave the way toward the identification of novel therapeutic targets against these infections.

Hilario J Ramos

Hilario J Ramos

Department of Immunology
University of Washington
Seattle, WA/Gilead Corp.

Dr. Ramos received his Ph.D. in Immunology from UT Southwestern Medical Center in 2009 under the mentorship of Dr. J. David Farrar.  More recently, Dr. Ramos’s work has focused on identifying the mechanism by which interleukin-1b (IL-1β) and type I interferon cross-talk to promote protective immunity against viral infection.  These studies have identified distinct IL-1β driven gene signatures that maintain classical interferon-stimulated gene responses to allow for optimal viral control.  This work has established a new way of thinking about inflammatory and type I IFN signaling integration that may promote new avenues for the development of therapeutics against disease states in which IL-1β and type IFN responses are prevalent.  Dr. Ramos is currently a member of the Gilead Sciences Discovery Virology group where he continues his work on cytokine driven viral/host interactions and the development of curative therapeutic interventions against inflammatory and viral diseases in humans.

John Schoggins

John Schoggins

Department of Microbiology
UT Southwestern Medical Center
Dallas, TX

Dr. Schoggins received his Ph.D. in 2007 from the Weill Cornell Graduate School of Biomedical Sciences and recently joined the faculty in the Department of Microbiology at UT Southwestern Medical Center. His current efforts are aimed at understanding the mechanisms of action of individual interferon stimulated genes that are otherwise uncharacterized. He is also interested in response of these genes against non-viral pathogens, such as bacteria and fungi, as well as species specific aspects of antiviral immunity. This ongoing work will further solidify our understanding of how the highly pleiotropic interferon system helps orchestrate innate defenses. Taking advantage of these naturally occurring virus inhibitors may be an effective strategy for future development of novel drugs to treat human viral diseases. Dr. Schoggins was elected as the ICIS Secretary for 2018 – 2020.